Affiliation:
1. Department of Medicine, University of Washington School of Medicine, and U.S. Public Health Service Hospital, Seattle, Washington 98104
Abstract
Cephapirin sodium, a parenterally administered derivative of cephalosporanic acid, was tested in vitro against 150 stock cultures of
Enterobacteriaceae
and 30 stock cultures each of
Pseudomonas aeruginosa
and
Staphylococcus aureus
. Both broth- and agar-dilution techniques were employed with two sizes of inocula of organisms. At a concentration of 7.5 μg or less/ml, cephapirin inhibited and killed 100% of strains of
Escherichia coli
and
Proteus mirabilis
and more than 80% of
Klebsiella
species when tested against an inoculum of 10
5
bacterial cells/ml. However, even at 100 μg/ml, only a few isolates of other
Enterobacteriaceae
and
Pseudomonas
were inhibited. A 100-fold increase in the inoculum resulted in decreased susceptibility of organisms. All penicillin-susceptible as well as penicillin-resistant
S. aureus
isolates were inhibited and killed by 5 μg or less of cephapirin/ml when tested with an inoculum of either 10
4
or 10
6
organisms/ml. The drug also was studied in various doses in the treatment of 77 patients with diverse infections. Cephapirin was effective in the treatment of 27 of 32 patients with pulmonary infection, as well as in 6 of 7 patients with staphylococcal or streptococcal soft tissue infection. Of 25 patients with urinary-tract infections, 19 developed a negative culture during therapy. A single 4-g intramuscular dose of cephapirin was effective in only 2 of 11 patients with gonococcal urethritis or endocervicitis. Two patients with gonococcal urethritis treated with multiple injections were cured. The drug was well tolerated except for pain at the site of injection in 14 patients and phlebitis in 4 patients. No abnormalities in renal or hepatic function could be attributed to cephapirin. In addition, no abnormalities were found in the renal tubules of rabbits challenged with 500 mg of cephapirin/kg. If further studies document that cephapirin is well tolerated by the parenteral route, it may have advantages over cephalothin or cephaloridine.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference11 articles.
1. Laboratory studies with a new cephalosporanic acid derivative;Chisholm D. R.;Antimicrob. Ag. Chemother.,1970
2. In vitro and in vivo evaluation of cephalexin;Clark H.;Antimicrob. Ag. Chemother.,1969
3. Laboratory and pharmacologic studies of BLP1322 (cephapirin sodium) in children;Gordon R. C.;Curr. Ther. Res.,1971
4. Factors determining the outcome of chemotherapy in infections of the urinary tract;Lindemeyer R.;Ann. Intern. Med.,1963
5. A critical evaluation of nalidixic acid in urinary tract infection;Ronald A. R.;N. Engl. J. Med.,1966
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献